EQS-News

AGP & DTx Summit: Digital therapeutics show 0.54% HbA1c reduction as diabetes care moves from monitoring to change 04.06.2026, 12:55 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: AGP & DTx Summit / Key word(s): Miscellaneous
AGP & DTx Summit: Digital therapeutics show 0.54% HbA1c reduction as diabetes care moves from monitoring to change

04.06.2026 / 12:55 CET/CEST
The issuer is solely responsible for the content of this announcement.


SHENZHEN, China, June 4, 2026 /PRNewswire/ -- In May 2026, the 4th AGP & DTx Summit concluded successfully in Shenzhen under the theme "Beyond Glucose." With SIBIONICS serving as a co-organizer, the summit brought together international experts, healthcare professionals, researchers, educators, and patient representatives to discuss how CGM data can move beyond monitoring and create real clinical value.

Across the summit, one message was clear: CGM should not be viewed only as a monitoring tool. Its greater value lies in translating glucose data into clinical insight, treatment decisions, and meaningful behavior change.

In the progress report of the International Consortium for AGP & DTx Research and Development, Prof. Andrej Janež shared that, over the past two years, the research fund has supported 20 investigator-initiated trials across 14 countries and regions. These studies focus on CGM and CKM-related research, including accuracy in special populations, dietary patterns and glycemic response, AI-enabled platforms, and clinical monitoring applications.

The clinical role of digital therapeutics was further highlighted by Prof. Sofianos Andrikopoulos. He noted that DTx can combine software-driven interventions, lifestyle guidance, medication support, and comprehensive care models. Evidence presented at the summit showed that DTx was associated with a mean HbA1c reduction of 0.54 percentage points, reinforcing its value in structured diabetes intervention.

From a clinical phenotyping perspective, Prof. Wei Qiang showed that combining routine admission metrics with CGM and AGP data may help identify metabolic phenotypes and treatment responses in hospitalized patients with type 2 diabetes, supporting more targeted and individualized care.

Prof. Shannon Lin noted that CGM alone may reach a plateau, making data-driven management essential. The study showed strong interest from both clinicians and patients in CGM integrated with AI for forecasting and personalized recommendations. Prof. Xiao Luo shared that her research found CGM combined with CKM can map glucose and ketone changes during fasting and eating cycles, making metabolic interventions more actionable.

Patient representative Tom Vesely, who has lived with type 1 diabetes for nearly 40 years, reminded the audience that CGM makes daily glucose changes visible — but the goal is not only better Time in Range, but more Time in Happiness.

Together, these discussions point to the next chapter of diabetes care: from monitoring to change.

CONTACT: ravian.luo@sibionics.com 

Cision View original content:https://www.prnewswire.co.uk/news-releases/agp--dtx-summit-digital-therapeutics-show-0-54-hba1c-reduction-as-diabetes-care-moves-from-monitoring-to-change-302791523.html

rt.gif?NewsItemId=EN76093&Transmission_Id=202606040652PR_NEWS_EURO_ND__EN76093&DateId=20260604


04.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2339894  04.06.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer